-
Article
Open AccessEvaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES
Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2–3 years from tamoxifen to exemestane. This PathIES aimed to assess the ro...
-
Article
Open AccessPrognostic value of microRNA expression in operable non-small cell lung cancer patients
About 50% of non-small cell lung cancer (NSCLC) patients develop distant metastases following pulmonary resection. Currently, there are no reliable factors allowing for individual selection of high-risk patien...
-
Article
Open AccessIncreased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC).
-
Article
Targeted therapies in advanced non-small cell lung cancer: success or failure?
The progress in molecular oncology has resulted in develo** numerous targeted anticancer agents, some of which have emerged as therapeutic options in non-small cell lung cancer (NSCLC). The largest clinical ...
-
Article
Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression
Purpose: The aim of this study was to assess the prognostic relevance of apoptotic index (AI), considered alone or together with expression of several proteins controlling G1 check point ...
-
Article
Open AccessA prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)
A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5...
-
Article
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer
The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine...
-
Chapter
Clinical relevance of genetic alterations in lung cancer
Lung cancer is the most common human malignancy in the world and its incidence is increasing. Each year there are almost one million deaths due to lung cancer worldwide, accounting for 40% of all cancer deaths...
-
Article
Influence of brachytherapy applicators geometry on dose distribution in cervical cancer
Although the relationship between the dose delivered to adjacent organs (urinary bladder and rectum) and the frequency and severity of treatment complications has been reported in many series, the factors infl...
-
Article
Post-operative radiotherapy in non-small-cell lung cancer: more questions than answers
-
Article
Sarcoma of the uterus
Records of 42 patients with a diagnosis of uterine sarcoma treated between 1974 and 1995 at the Department of Oncology and Radiotherapy, Medical University of Gda′nsk have been reviewed. There were 15 cases o...
-
Article
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study
Between April 1986 and May 1989 a multicéntre study was conducted to evaluate the efficacy of a 4-h intravenous infusion of 1000 mg/m2 5-fluorouracil (5-FU) followed by a 1-h infusion of 25 mg/m2 cisplatin (CDDP)...
-
Article
Phase II study of 4′-Epi-Doxorubicin in patients with untreated, extensive small Cell Lung Cancer
The purpose of the study was to investigate the antitumour activity and toxicity of high dose (120 mg m-2) single agent epirubicin therapy in untreated extensive small cell lung cancer patients. Out of 80 patient...
